Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response

Objectives In this study, we sought to investigate whether there was any association between genetically regulated gene expression (as predicted using various reference panels) and anti-tumour necrosis factor (anti-TNF) treatment response (change in erythrocyte sedimentation rate (ESR)) using 3158 European ancestry patients with rheumatoid arthritis. Methods The genetically regulated portion of gene expression was estimated in the full cohort of 3158 subjects (as well as within a subcohort consisting of 1575 UK patients) using the PrediXcan software package with three different reference panels. Estimated expression was tested for association with anti-TNF treatment response. As a replication/validation experiment, we also investigated the correlation between change in ESR with measured gene expression at the Interleukin 18 Receptor Accessory Protein (IL18RAP) gene in whole blood and synovial tissue, using an independent replication data set of patients receiving conventional synthetic disease modifying anti-rheumatic drugs, with directly measured (via RNA sequencing) gene expression. Results We found that predicted expression of IL18RAP showed a consistent signal of association with treatment response across the reference panels. In our independent replication data set, IL18RAP expression in whole blood showed correlation with the change in ESR between baseline and follow-up (r=−0.35, p=0.0091). Change in ESR was also correlated with the expression of IL18RAP in synovial tissue (r=−0.28, p=0.02). Conclusion Our results suggest that IL18RAP expression is worthy of further investigation as a potential predictor of treatment response in rheumatoid arthritis that is not specific to a particular drug type.

[1]  S. Kummerfeld,et al.  Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes , 2019, Cell reports.

[2]  Nir Hacohen,et al.  Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry , 2019, Nature Immunology.

[3]  J. Barrett,et al.  Prediction of treatment response in rheumatoid arthritis patients using genome‐wide SNP data , 2018, Genetic epidemiology.

[4]  P. McKeigue,et al.  Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis , 2018, The Pharmacogenomics Journal.

[5]  Heather J. Cordell,et al.  Comparison of methods for transcriptome imputation through application to two common complex diseases , 2018, European Journal of Human Genetics.

[6]  Andrew Butler,et al.  Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation , 2018, Nature Communications.

[7]  A. Barton,et al.  Stratified medicine in rheumatoid arthritis—the MATURA programme , 2016, Rheumatology.

[8]  Kaanan P. Shah,et al.  A gene-based association method for mapping traits using reference transcriptome data , 2015, Nature Genetics.

[9]  Cesare Furlanello,et al.  A promoter-level mammalian expression atlas , 2015 .

[10]  Sandra Romero-Steiner,et al.  Molecular signatures of antibody responses derived from a systems biological study of 5 human vaccines , 2013, Nature Immunology.

[11]  D. Koller,et al.  Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals , 2013, Genome research.

[12]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[13]  Jing Cui,et al.  Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis , 2013, PLoS genetics.

[14]  R. Durbin,et al.  Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses , 2012, Nature Protocols.

[15]  A. Koch,et al.  Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  Daniel R. Salomon,et al.  Strategies for aggregating gene expression data: The collapseRows R function , 2011, BMC Bioinformatics.

[17]  Andrey A. Shabalin,et al.  Matrix eQTL: ultra fast eQTL analysis via large matrix operations , 2011, Bioinform..

[18]  A. Morris,et al.  Data quality control in genetic case-control association studies , 2010, Nature Protocols.

[19]  Andreas Radbruch,et al.  Does gene expression analysis inform us in rheumatoid arthritis? , 2009, Annals of the rheumatic diseases.

[20]  Sara Marsal,et al.  An Eight-Gene Blood Expression Profile Predicts the Response to Infliximab in Rheumatoid Arthritis , 2009, PLoS ONE.

[21]  M. Tanino,et al.  Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. , 2009, Biochemical and biophysical research communications.

[22]  M. Daveau,et al.  Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis , 2006, Arthritis research & therapy.

[23]  L. Simon,et al.  Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk , 2006, Arthritis research & therapy.

[24]  K. Yudoh,et al.  Implication of interleukin 18 in production of matrix metalloproteinases in articular chondrocytes in arthritis: direct effect on chondrocytes may not be pivotal , 2005, Annals of the rheumatic diseases.

[25]  Iain B McInnes,et al.  Interleukin-18: a therapeutic target in rheumatoid arthritis? , 2004, Arthritis research & therapy.

[26]  B. Bresnihan,et al.  Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis , 2004, Annals of the rheumatic diseases.

[27]  L. Joosten,et al.  Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[28]  I. McInnes,et al.  Role of interleukin 15 and interleukin 18 in inflammatory response , 2002, Annals of the rheumatic diseases.

[29]  P. van Riel,et al.  Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. , 2002, Rheumatology.

[30]  I. Julkunen,et al.  IFN-α and IL-12 Induce IL-18 Receptor Gene Expression in Human NK and T Cells1 , 2000, The Journal of Immunology.

[31]  I. McInnes,et al.  A proinflammatory role for IL-18 in rheumatoid arthritis. , 1999, The Journal of clinical investigation.

[32]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[33]  A. Silman,et al.  Predictors of Response to Anti-tnf-therapy among Patients with Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register , 2022 .